Hypothalamic-Pituitary-Somatotropic Axis

The somatotropic axis is the regulatory loop running from the hypothalamus to the anterior pituitary to the peripheral tissues, chiefly the liver. Two hypothalamic peptides oppose each other at the somatotroph: GHRH drives secretion, somatostatin suppresses it, and their alternating dominance generates the pulses that characterise growth hormone release. Ghrelin, from stomach and hypothalamus, is a third input through a separate receptor. Growth hormone then acts on its receptor in liver and other tissues to induce IGF-1.

Each layer can fail independently, and telling them apart is the whole clinical point. Hypothalamic disease leaves a pituitary that still responds to exogenous GHRH; pituitary disease does not. Growth hormone receptor mutations produce Laron syndrome, in which growth hormone is high and IGF-1 is low, the mirror image of pituitary failure. Acromegaly is the axis driven from the top by an autonomous somatotroph adenoma, with IGF-1 elevated and no suppression after oral glucose.

The axis converts a vague question about growth hormone status into an ordered set of measurements: a stimulated peak, an age-adjusted IGF-1, binding proteins, and imaging of the sella. A single result rarely means anything on its own. It also explains why the axis has a natural ceiling under stimulation, and why bypassing it with injected growth hormone changes the exposure pattern rather than merely its amount.

The common misreading is to treat the axis as a single dial with a number attached. Growth hormone and IGF-1 do not move in lockstep: nutrition, portal insulin, hypothyroidism, liver disease and oestrogen all uncouple them, and oral oestrogen in particular blunts hepatic IGF-1 while growth hormone rises. Marketing that presents a raised IGF-1 as proof of a healthier axis ignores that the same value is the treatment target in acromegaly.